Subject: Specialty Quantity Limit Dupixent 1692-H P2026b

Policy:

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member’s plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

Covered Quantities

Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

Medication	Standard Limit	Exception Limit
Dupixent (dupilumab) 200 mg/1.14 mL pre-filled syringe/pen	2 syringes/pens per 28 days	2 syringes/pens per 14 days
Dupixent (dupilumab) 300 mg/2 mL pre-filled syringe/pen	4 syringes/pens per 28 days	N/A

FDA-Recommended Dosing

Atopic Dermatitis

Adults and pediatrics 6 years to 17 years of age weighing ≥ 60 kg: Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every 2 weeks

Pediatrics 6 years to 17 years of age:

·        30 to < 60 kg: Initial dose of 400 mg (two 200 mg injections), followed by 200 mg every 2 weeks

·        15 to < 30 kg: Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every 4 weeks

Pediatrics 6 months to 5 years of age:

·        15 to < 30 kg: 300 mg every 4 weeks

·        5 to < 15 kg: 200 mg every 4 weeks

Asthma

Adults and pediatrics 12 years and older:

·        Initial dose of 400 mg (two 200 mg injections), followed by 200 mg every 2 weeks, or

·        Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every 2 weeks

·        Patients with oral corticosteroid-dependent asthma, or with co-morbid moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, or allergic fungal rhinosinusitis for which Dupixent is indicated: Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every 2 weeks

Pediatrics 6 years to 11 years of age:

·        ≥ 30 kg: 200 mg every 2 weeks

·        15 to < 30 kg: 300 mg every 4 weeks

·        Patients with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended dosage for atopic dermatitis

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Adults and pediatrics 12 years and older: 300 mg every 2 weeks

Eosinophilic Esophagitis (EoE)

Adults and pediatrics 1 year and older:

·        ≥ 40 kg: 300 mg every week

·        30 to < 40 kg: 300 mg every 2 weeks

·        15 to < 30 kg: 200 mg every 2 weeks

Prurigo Nodularis for Adults

Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every 2 weeks

Chronic Obstructive Pulmonary Disease (COPD) for Adults

300 mg every 2 weeks

Chronic Spontaneous Urticaria (CSU)

Adults and pediatrics 12 years to 17 years of age weighing ≥ 60 kg: Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every 2 weeks

Pediatrics 12 years to 17 years of age weighing 30 to < 60 kg: Initial dose of 400 mg (two 200 mg injections), followed by 200 mg every 2 weeks

Bullous Pemphigoid (BP) for Adults

Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every 2 weeks

Use in combination with a tapering course of oral corticosteroids. Once disease control has occurred, gradually taper corticosteroids after which continue as monotherapy. In case of relapse, corticosteroids may be added if medically advisable.

Allergic Fungal Rhinosinusitis (AFRS)

Adults and pediatrics 6 years to 17 years of age weighing ≥ 60 kg: 300 mg every 2 weeks

Pediatrics 6 years to 17 years of age weighing 30 to < 60 kg: 200 mg every 2 weeks

Pediatrics 6 years to 17 years of age weighing 15 to < 30 kg: 300 mg every 4 weeks

Place of Service:

Outpatient

The above policy is based on the following references:

1.      Dupixent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; February 2026.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

August 16, 2026